Back

Mid-term renal impact of SGLT2 inhibitors in heart failure: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Targeting metabolism in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Akshat Sinha

Sandwell and West Birmingham Hospitals NHS Trust, Birmingham (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Epicardial adipose tissue, functional status, and invasive exercise hemodynamics in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.
Doctor T. Gorter (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
The effect of GLP-1 receptor agonists on obstructive sleep apnea in ambulatory patients with HFpEF, obesity, and type 2 diabetes.
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Impact of Na+/glucose cotransporter 2 (SGLT2) inhibitor therapy on biventricular ventricular-arterial coupling in patients with heart failure with reduced ejection fraction
Miss C. Madaudo (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
High-protein diet ameliorates anthracycline-induced cardiotoxicity in mice
Miss A. Diaz-Guerra Priego (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
The effect of malnutrition on the efficacy and safety of empagliflozin: a post hoc analysis of the EMPEROR-Reduced trial
Doctor W. Li (Chengdu, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Targeting metabolism in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Impact of kidney dysfunction on the initiation and discontinuation of SGLT2 inhibitor therapy in patients with heart failure: a nationwide study of 41,225 patients
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources